Short-Course Anti-tuberculosis Regimens for Mild Spinal Tuberculosis

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2025
To evaluate the non-inferiority in efficacy between the rifapentine- and moxifloxacin-containing short-course regimens (with rifampicin replaced by rifapentine and ethambutol replaced by moxifloxacin, while isoniazid and pyrazinamide remaining the same as the empirical regimen) and the empirical long-course regimen, so as to determine whether it is possible to shorten the treatment duration to 26 weeks for patients with mild spinal tuberculosis.
Epistemonikos ID: 502c64926c84f527dfe282e35abb90a2689ea3d6
First added on: Apr 09, 2025